epiglucan and Toxoplasmosis--Animal

Chronic Toxoplasma gondii (T. gondii) infection has been revealed to be a risk factor for neuropsychiatric diseases, including anxiety. However, there is no intervention strategy. The present study aimed to investigate the protective effect of β-glucan on T. gondii Wh6 strain-induced anxiety-like behavior in mice. The anxiety mouse model was established by infection with 10 cysts of the T. gondii Wh6 strain. β-Glucan was intraperitoneally administered 2 weeks before infection. Open field and elevated plus maze tests were performed to assess anxiety-like behavior. In the open field test, Wh6-infected mice spent less time in the central zone and had fewer entries into the central zone. In the elevated plus maze test, the infection reduced the frequency and time of head entries in the open arms. These results showed that Wh6 causes anxiety-like behavior in mice. Interestingly, the administration of β-glucan significantly ameliorated anxiety-like behavioral performance. The present study shows that β-glucan can alleviate the anxiety-like behavior induced by chronic T. gondii infection in mice, which indicates that β-glucan may be a potential drug candidate for treating T. gondii-related mental disorders, including anxiety.

Topics: Animals; Anxiety; beta-Glucans; Disease Models, Animal; Mice; Toxoplasma; Toxoplasmosis; Toxoplasmosis, Animal

Toxoplasmosis which is caused by Toxoplasma gondii, has a high risk of fetal infection development if the infection occurs during pregnancy. Treatment with oral spiramycin is recommended during pregnancy in order to prevent the transmission of protozoa to fetus and development of infection. Since beta- glucan is known to stimulate the immune system and increase the phagocytic activity of the cells, it has been shown to exhibit immunomodulatory effect on many infectious diseases. The objectives of this study were to investigate the effectiveness of beta-glucan alone and in combination with spiramycin and to determinate the levels of interlökin (IL)-10, IL-12 and tumor nekrosis factor (TNF)-α in mice experimentally infected with T.gondii. For this purpose, four experimental groups each consisting of eight BALB/c mice, were formed with the approval of Ethics Committee for the Animal Experiments. All the mice were infected with 2 ml of suspension containing 2 x 102/ml of trophozoite prepared from T.gondii RH strain (Refik Saydam National Public Health Agency, Parasitology Laboratory of Communicable Diseases Research Department, Ankara, Turkey), by intraperitoneal injection. Twenty-four hours after the infection, beta-glucan (3 mg/day) was given to the beta-glucan group, spiramycin (200 mg/kg/day) to the spiramycin group, beta-glucan (3 mg/day) plus spiramycin (200 mg/kg/day) to the beta-glucan-spiramycin (BG-S) group by oral gavage. The fourth group which was the control group was infected but untreated. The above administration was carried out for seven days. On the 8th day, under anaesthesia, 1 ml normal saline was given into the peritoneum, drawn back later and the number of trophozoites in 1 ml of peritoneal fluid was determined by counting them on the Thoma slide. Moreover, by drawing the heart blood; IL-10, IL-12, TNF-α levels were determined in serum samples by ELISA method (eBioscience Platinum, Austria). The number of trophozoites in the BG-S group was found significantly lower than the number of trophozoites in control, beta-glucan and spiramycin groups (p< 0.05). There was no significant difference between the beta-glucan and spiramycin groups, however the number of trophozoites in both groups was significantly lower than the number of trophozoites in the control group (p< 0.05). There was a certain decrease in IL-10 level in spiramycin and BG-S groups, compared to the control group, in addition when IL-10 levels in spiramycin and BG-S groups were

Topics: Acute Disease; Animals; beta-Glucans; Coccidiostats; Cytokines; Drug Therapy, Combination; Female; Interleukin-10; Interleukin-12; Mice; Mice, Inbred BALB C; Spiramycin; Toxoplasmosis, Animal; Tumor Necrosis Factor-alpha

The present study tested the action of Beta-glucan in swine experimentally infected with tachyzoites of Toxoplasma gondii. The experiment design used 8 mixed breed pigs (21 days) divided into three groups: G1 (Beta-glucan treated and infected, n = 3), G2 (untreated and infected, n = 3), and G3 (untreated uninfected, n = 2). The G1 animals were treated with 1g of Beta-glucan by intramuscularly route at days 0, 14, and 28 before experimental infection, while the other groups (G2 and G3) received only saline. The G1 and G2 were infected with viable tachyzoites (107) of the RH strain at day 35 of experiment. The parasitemy was determined by mouse bioassay and PCR from whole blood of each swine, obtained at days 3, 7, 14, 21, 31, 39, 47 e 69 post infections. The antibody levels of serum, aqueous and vitreous humor were measured by indirect immunofluorescence assay (IFA); a title >/= 64 was considered as positive. There were differences in the hematocrit, hemoglobin, plasmatic proteins, and eosinophils values between groups (P< 0.05). The swine of G1 and G2 serum converted 7 days post infection, and the highest title observed was 1024 in two pigs. Samples of aqueous and vitreous humor did not show antibodies against T. gondii. Parasite was detected of whole blood on days 3, 14, 31, 39, and 47 in two animals from G1, and three animals from G2. There were no differences between PCR and mouse bioassay. Animals from G3 remained without parasitemy by both PCR and bioassay throughout the experiment. The use of Beta-glucan, as was used here, was not protective for pigs against T. gondii tachyzoites acute infection. Additionally, the lineage of RH strain showed nonpersistent for pigs (muscles and retina) 69 days after infection.

Topics: Animals; beta-Glucans; Swine; Swine Diseases; Toxoplasmosis, Animal